...
首页> 外文期刊>Clean - Soil, Air, Water: A Journal of Sustainability and Environmental Safety >Status update of modified oligonucleotides for chemotherapeutics
【24h】

Status update of modified oligonucleotides for chemotherapeutics

机译:用于化疗的改良寡核苷酸的现状更新

获取原文
获取原文并翻译 | 示例
           

摘要

Duringthe past decade, the number of therapeutic oligonucleotides in clinical trials has nearly tripled. This is primarily due to advances in the synthesis protocols, better understanding of the biology, improved delivery, and improved formulation technologies. Currently, over 100 clinical trials with oligonucleotide-based drugs are ongoing in the United States for potential treatment of a variety of life-threatening diseases. Among the various oligonucleotides, antisense technology has been at the forefront, with one product on the market. Antisense technologies represent about half of the ongoing clinical trials.
机译:在过去十年中,临床试验中的治疗性寡核苷酸数量几乎增加了两倍。这主要是由于合成方案的进步、对生物学的更好理解、改进的递送和改进的配方技术。目前,美国正在进行100多项基于寡核苷酸的药物临床试验,以潜在地治疗各种危及生命的疾病。在各种寡核苷酸中,反义技术一直走在前列,市场上只有一种产品。反义技术约占正在进行的临床试验的一半。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号